| Browse All

Pasithea Therapeutics Corp. (KTTAW)

Miami Beach, United States | NasdaqCM
0.01 USD

Short-term: ☆☆☆☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆
Hot Take | April 11, 2026, 4:01 p.m. EDT

KTTAW (Pasithea Therapeutics Corp.) presents a highly volatile and uncertain investment opportunity. The stock has shown no significant price movement over the last 14 days, with all closing prices at 0.01, and the current price is at the 52-week low and high. The company's fundamentals are weak, with negative return on assets and equity, and negative cash flows. There is no dividend history, and the forecasting model provides no reliable predictions for the next 45 days. Given the lack of momentum, poor fundamentals, and no dividend yield, this stock is not suitable for short-term or long-term investment at this time.

None
Attribute Value
Beta 0.25
Website https://www.pasithea.com

Info Dump

Attribute Value
Address1 1,111 Lincoln Road
Address2 Suite 500
Ask 0.0
Ask Size 0
Beta 0.253
Bid 0.0
Bid Size 0
Book Value 2.391
City Miami Beach
Compensation As Of Epoch Date 1,767,139,200
Country United States
Crypto Tradeable 0
Currency USD
Current Price 0.0071
Current Ratio 11.351
Custom Price Alert Confidence HIGH
Day High 0.0075
Day Low 0.0071
Display Name Pasithea Therapeutics
Ebitda -16,031,099
Ebitda Margins 0.0
Esg Populated 0
Exchange NCM
Exchange Data Delayed By 0
Exchange Timezone Name America/New_York
Exchange Timezone Short Name EDT
Fifty Two Week High 0.0075
Fifty Two Week High Change -0.0003999998
Fifty Two Week High Change Percent -0.053333305
Fifty Two Week Low 0.0071
Fifty Two Week Low Change 0.0
Fifty Two Week Low Change Percent 0.0
Fifty Two Week Range 0.0071 - 0.0075
Financial Currency USD
First Trade Date Milliseconds 1,772,807,400,000
Float Shares 14,262,408
Free Cashflow -6,473,837
Full Exchange Name NasdaqCM
Full Time Employees 5
Gmt Off Set Milliseconds -14,400,000
Gross Margins 0.0
Has Pre Post Market Data 1
Industry
Industry Key
Ipo Expected Date 2,021-09-15
Language en-US
Long Business Summary Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumors; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Long Name Pasithea Therapeutics Corp.
Market us_market
Market State POST
Max Age 86,400
Message Board Id finmb_702706441
Net Income To Common -20,427,684
Open 0.0122
Operating Cashflow -15,211,490
Operating Margins 0.0
Phone 786 977 3380
Previous Close 0.0071
Price Hint 4
Price To Book 0.0029694687
Profit Margins 0.0
Quick Ratio 11.09
Quote Source Name Delayed Quote
Quote Type EQUITY
Recommendation Key none
Region US
Regular Market Change 0.0
Regular Market Change Percent 0.0
Regular Market Day High 0.0075
Regular Market Day Low 0.0071
Regular Market Day Range 0.0071 - 0.0075
Regular Market Open 0.0122
Regular Market Previous Close 0.0071
Regular Market Price 0.0071
Regular Market Time 1,775,741,401
Regular Market Volume 11,000
Return On Assets -0.27347
Return On Equity -0.58362997
Sand P52 Week Change 0.36506534
Sector
Sector Key
Short Name Pasithea Therapeutics Corp. Warrant
Source Interval 15
State FL
Symbol KTTAW
Total Cash 55,158,940
Total Cash Per Share 2.212
Total Debt 0
Tradeable 0
Trailing Annual Dividend Rate 0.0
Trailing Annual Dividend Yield 0.0
Trailing Peg Ratio None
Triggerable 1
Type Disp Equity
Volume 11,000
Website https://www.pasithea.com
Zip 33,139